“Adverse pathology is a clear predictor of long-term outcomes for patients,” says Eric A. Klein, MD.
In this video, Eric A. Klein, MD, discusses the background and findings of the recent Urologic Oncology: Seminars and Original Investigations study, Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy, for which he served as senior author. Klein is the emeritus chair of the Cleveland Clinic Glickman Urological & Kidney Institute.
Study links PARP inhibitors to increased risk of hematologic toxicity in mCRPC patients
November 23rd 2023A recently published study found an association between PARP inhibitor treatment and an increased risk of hematological adverse events, including anemia, thrombocytopenia, and neutropenia, in patients with metastatic castration-resistant prostate cancer.
Mistrust of medical research may discourage genetic testing in prostate cancer
November 20th 2023According to the survey, 79% of Black men know that genetic information can help improve prostate cancer outcomes, yet 33% indicated that they would be unwilling or uncertain to provide DNA samples, even if it meant finding new treatment options.